Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BRAFV600E Mutation Enhances Age-Based Prognostic Stratification in Radioiodine-Treated Papillary Thyroid Cancer: A Retrospective Cohort Study.

Clinical oncology (Royal College of Radiologists (Great Britain)) - 1 Dec 2025

Cao J, Liang H, Li X, Guan X, Ma Y Z, Li J

Abstract excerpt

AIMS: To evaluate whether BRAFV600E mutation status enhances the value of age in predicting clinical outcomes for papillary thyroid carcinoma (PTC) patients receiving radioactive iodide (RAI) therapy. MATERIALS AND METHODS: We conducted a retrospective analysis of 1160 PTC patients treated with RAI therapy. Patients were stratified by age (≤18, 18-55, and ≥55 years) and BRAFV600E status. Clinicopathological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Age Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Young Adult

Source

Identifiers

PMID: 41072224
DOI: 10.1016/j.clon.2025.103945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BRAFV600E Mutation Enhances Age-Based Prognostic Stratification in Radioiodine-Treated Papillary Thyroid Cancer: A Retrospective Cohort Study.PMID 41072224Read ↗

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.Semantic proximity Read ↗

Impact of age on genomic alterations and the tumor immune microenvironment in papillary thyroid cancer.Semantic proximity Read ↗

BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.Semantic proximity Read ↗

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapySemantic proximity Read ↗

Association of BRAF Mutation with Treatment Response and Prognostic Factors in Papillary Thyroid Carcinoma: A Retrospective Cohort StudySemantic proximity Read ↗

BRAF mutation and age in differentiated thyroid cancer risk stratification: Two sides of the same coin.Semantic proximity Read ↗

Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.Semantic proximity Read ↗

A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.Semantic proximity Read ↗

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.Semantic proximity Read ↗

Prognostic utility of BRAF mutation in papillary thyroid cancer.Semantic proximity Read ↗

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years OldSemantic proximity Read ↗

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.